Sponsored by
Merck

BioCanRx 2021 Public Forum

Understanding Cancer Immunotherapy Clinical Trials in Canada: Are they Needed Now More than Ever?

Saturday, November 20, 2021, at 2:00 – 3:30pm Eastern Time

BioCanRx is very pleased to host our 5th annual Public Forum in conjunction with our scientific conference – the Summit for Cancer Immunotherapy. In this year's virtual forum we'll hear from a clinical trials doctor, a patient partner who has participated in a clinical trial and a scientist who will speak about the latest developments in immunotherapy cancer research and treatments.

Key themes covered:

  • Value of clinical trials in making effective therapies available to patients
  • How do cancer patients access clinical trials?
  • How have clinical trials pivoted during COVID-19 and what are the impacts for future care?
  • Conversations you can have with your physician

Who should attend

This FREE virtual public forum is open to everyone and is targeted toward individuals seeking to learn more about immuno-oncology clinical trials in Canada.

Format

The 1.5-hour session will include a panel discussion and ample time for Q&A from the audience.

Speakers

Louise Binder
Kelvin Chan
John Bell
David McMullen
Lacey Pitre
Stéphanie Michaud
Register here

Who is BioCanRx?

BioCanRx, Canada's Immunotherapy Network, is a network of scientists, clinicians, cancer stakeholders, academic institutions, NGOs and industry partners working together to accelerate the development of leading-edge immune oncology therapies for the benefit of patients. Our vision is to cure patients and enhance the quality of life of those living with cancer. BioCanRx invests in leading edge immune oncology research translating world-class technologies from the lab into early phase clinical trials. BioCanRx provides researchers with access to funding, expertise, training and manufacturing facilities and is a leader in the translation, manufacture and adoption of cancer immunotherapies. The network is committed to training and developing the talent needed for a thriving health biotechnology sector in Canada. BioCanRx receives funding from the federal government's Networks of Centres of Excellence, and support from industry, the provinces and charities. The network is hosted by the Ottawa Hospital Research Institute.
https://biocanrx.com/


Speaker Bios

John Bell

John Bell

BioCanRx; The Ottawa Hospital; University of Ottawa

Dr. John Bell is a world-renowned thought leader in oncolytic virus research and development. In addition to his many academic contributions to the field, Dr. Bell established a GMP manufacturing program that has produced clinical grade oncolytic viruses for worldwide use in phase I and II clinical trials. Dr. Bell co-founded and was the Chief Scientific Officer of Jennerex Biotherapeutics, which was acquired by SillaJen. Dr. Bell also co-founded Turnstone LP, an enterprise linking four Canadian research institutes to drive the clinical and commercial development of a proprietary next-generation oncolytic vaccine platform. Dr. Bell is a Senior Scientist with The Ottawa Hospital and Professor of Medicine and Biochemistry, Microbiology and Immunology at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. He is the Scientific Director of BioCanRx, Canada's Immunotherapy Network, and a Network Of Centres of Excellence. Dr. Bell is also a fellow of the Royal Society of Canada.


Louise Binder

Louise Binder

Save Your Skin Foundation

Louise Binder is a lawyer and health advocate who has been involved in informing the development of health policy and systemic treatment access practices from the patient perspective since the early 1990's subsequent to her own HIV diagnosis. She co-founded the Canadian Treatment Action Council (CTAC) in 1996. Louise began similar work in the cancer area and is presently a Health Policy Consultation with the Save Your Skin Foundation. She has been recognized by many organizations for her work, including receiving an Honorary Doctorate of Laws from her alma mater, Queen's Law School; the Order of Ontario from the Province of Ontario; and two Queen Elizabeth II medals.


Kelvin Chan

Kelvin Chan

Sunnybrook Odette Cancer Centre; University of Toronto; Sunnybrook Research Institute

Dr. Kelvin Chan is a medical oncologist at the Sunnybrook Odette Cancer Centre, an Associate Professor at the University of Toronto, and an associate scientist at the Sunnybrook Research Institute. He specializes in GI oncology and Head and Neck oncology.

As a health economist, clinical epidemiologist and biostatistician, Dr. Chan's research interests include health services research, health technology assessment, meta-analysis including network meta-analysis, cost-effectiveness analyses, and statistical methods research in health economics. He is the Co-Director at the Canadian Centre for Applied Research in Cancer Control (ARCC), funded by the Canadian Cancer Society (CCS).

Professionally, Dr. Chan has an interest in cancer drug reimbursement related issues. He is a member of multiple provincial and national committees related to cancer drug assessments and recommendations including the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC), the Committee to Evaluate Drug (CED) and the Interim Chair for the Ontario Steering Committee of Cancer Drugs (OSCCD), Ontario MOHLTC and Cancer Care Ontario. He is also the Clinical Lead for the Provincial Drug Reimbursement Programs (PDRP) at Cancer Care Ontario (CCO).


David McMullen

David McMullen

Patient Advocate and Clinical Trial Participant

David has been a Professional Engineer, working 37 years with Ontario Power Generation. He has held various management, engineering, plant maintenance, and business planning roles in large electric power stations.

In 2012, he was diagnosed with multiple myeloma, an incurable hematologic cancer. Since then, David has had two stem cell transplants and a variety of other treatments, including participation in a phase 1 clinical trial. Since his diagnosis, he has become very active with Myeloma Canada, a successful patient-based charitable organization, in various patient support, education, advocacy, research, awareness, and fundraising activities. He is also active on several myeloma patient support groups in southern Ontario, including his role as long-term chair of the Toronto and District Multiple Myeloma Support Group. David is the founding chair of the nation-wide Myeloma Canada Patient Advisory Council, where he was an ex-officio member of the Board of Directors.

Since 2015, he’s been an active Patient Representative in the Cancer Clinical Trials Group, in the Hematology Disease Site Committee, and previously in the Quality of Life Committee and Melanoma Disease Site Committee. David is also a member of the CADTH Patient and Community Advisory Committee.

David has a strong interest in treatment research and feels privileged to know many hundreds of myeloma patients across Canada.


Stéphanie Michaud

Stéphanie Michaud

BioCanRx

Dr. Stéphanie Michaud is the President and CEO of BioCanRx, a not-for-profit that seeks to accelerate the delivery of innovative immunotherapies from the bench to the bedside. In this position, Stéphanie is responsible for running all facets of the organization. She brings more than 20 years of public, government and private sector experience in research and Science & Technology innovation policy. She strives to create partnerships between government, not-for-profits, academia and industry to maximize the impact of research funded by the BioCanRx network on the lives of those affected by cancer.

Prior to joining BioCanRx, Stéphanie was Deputy Director of the flagship Government of Canada Networks Centres of Excellence (NCE) program. In addition to responsibility for its performance, management and delivery, she led the implementation of high profile bilateral international initiatives and provided strategic advice to government and stakeholders. She is a strong contributor to S&T policy, most notably in intellectual property. Dr. Michaud also currently sits on the Research Canada Board of Directors.

Dr. Michaud earned a PhD in Organic Chemistry from McGill University. She is involved with a number of not-for-profit organizations and is a member of the Board of Directors of the Stem Cell Network.


Lacey Pitre

Lacey Pitre

Northeast Cancer Centre; Northern Ontario School of Medicine

Dr. Lacey Pitre is originally from Sudbury, ON and graduated from the Northern Ontario School of Medicine (NOSM) in 2010. She completed her Internal Medicine residency and Medical Oncology fellowship at McMaster University. She is currently in her fifth year of practice at the Northeast Cancer Centre in Sudbury and specializes in breast and lung cancers. She is the Lead for Cancer Clinical Trials at her centre and is the local principal investigator on several clinical trials in the breast, lung and head & neck field. She is an assistant professor at NOSM and is the Cancer Care Ontario Lead for Systemic Therapy for the Northeastern Ontario region.